RE: china18 Jun 2022 21:32
The Mcap of Cizzle Biotechnology upon relist in 2021 was around £28M, we are now at £4.7M as well as having made serious progress on getting the blood test to market globally.
There is a huge disconnect to the current Mcap and what is on offer here and that's assuming we are not bought out by a global biotech company in the mean time.
Even though this only relisted in 2021, Cizzle has been in the research and development stage since around 2005, everything over the last 17yrs has been leading up to this critical point.
This was an interesting comment from the other day....
"I recently attended ASCO22, a major clinical sciences conference in Chicago, USA, where multiple meetings evidenced considerable interest in Cizzle Biotechnology's entry into the USA. Cizzle Biotechnology fits perfectly with the Behnke Group's mission to achieve better outcomes, lower costs and improve the health and safety of patients. We are excited to add Cizzle Biotechnology to our portfolio of game changing businesses."
Next update could be game changing....